Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Obesity Surgery
Published in: Obesity Surgery 5/2010

01-05-2010 | Review

A Review of Weight Loss Following Roux-en-Y Gastric Bypass vs Restrictive Bariatric Surgery: Impact on Adiponectin and Insulin

Authors: Katrina L. Butner, Sharon M. Nickols-Richardson, Susan F. Clark, Warren K. Ramp, William G. Herbert

Published in: Obesity Surgery | Issue 5/2010

Login to get access

Abstract

Background

Bariatric surgery is a common procedure often used to ameliorate comorbidities associated with obesity, including type 2 diabetes. Substantial weight loss leads to alterations in inflammation and insulin sensitivity as well as numerous metabolic and physiologic pathways. Several inflammatory markers have been evaluated, yet adiponectin, an anti-inflammatory adipokine, has not been fully investigated. Adiponectin may play a key role as a mediator between obesity and inflammation, as lower blood levels are more commonly associated with obesity and type 2 diabetes and because adiponectin lessens insulin resistance. This review evaluates outcome variables from patients who underwent Roux-en-Y gastric bypass (RYGB) or restrictive bariatric surgery to compare and contrast any differential surgical impacts on weight loss, adiponectin, and insulin.

Methods

A systematic literature review was conducted using a PubMed search. Published studies from 1999 to 2009 that measured blood levels of adiponectin and insulin in bariatric surgery patients prior to and at least 6 months after surgery were included.

Results

Eighteen studies met inclusion criteria for evaluation. RYGB surgery compared to restrictive surgery led to significantly greater weight loss and improvements in adiponectin and insulin sensitivity. Despite significant weight loss, many patients did not achieve “healthy” body mass index or normalization of inflammatory markers.

Conclusions

While RYGB surgery appears to more favorably influence body weight and inflammatory markers, data are insufficient to fully understand the impact of bariatric surgery on changes in adiponectin and insulin and related health implications. Long-term research is needed to more thoroughly evaluate inflammatory outcomes following these two bariatric surgery procedures.
Literature
1.
Taylor K. Metabolic and bariatric surgery: fact sheet. Gainesville: American Society for Metabolic and Bariatric Surgery; 2008.
2.
Tice JA, Karliner L, Walsh J, et al. Gastric banding or bypass? A systematic review comparing the two most popular bariatric procedures. Am J Med. 2008;121:885–93.CrossRefPubMed
3.
Shinogle JA, Owings MF, Kozak LJ. Gastric bypass as treatment for obesity: trends, characteristics, and complications. Obes Res. 2005;13:2202–9.CrossRefPubMed
4.
Guerre-Millo M. Adiponectin: an update. Diabetes Metab. 2008;34:12–8.PubMed
5.
Ballantyne GH, Gumbs A, Modlin IM. Changes in insulin resistance following bariatric surgery and the adipoinsular axis: role of the adipocytokines, leptin, adiponectin and resistin. Obes Surg. 2005;15:692–9.CrossRefPubMed
6.
Forsythe LK, Wallace JM, Livingstone MB. Obesity and inflammation: the effects of weight loss. Nutr Res Rev. 2008;21:117–33.CrossRefPubMed
7.
Vetter ML, Cardillo S, Rickels MR, et al. Narrative review: effect of bariatric surgery on type 2 diabetes mellitus. Ann Intern Med. 2009;150:94–103.PubMed
8.
Compher C, Badellino KO. Obesity and inflammation: lessons from bariatric surgery. JPEN J Parenter Enteral Nutr. 2008;32:645–7.CrossRefPubMed
9.
Holdstock C, Engstrom BE, Ohrvall M, et al. Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in obese humans. J Clin Endocrinol Metab. 2003;88:3177–83.CrossRefPubMed
10.
Couce ME, Cottam D, Esplen J, et al. Is ghrelin the culprit for weight loss after gastric bypass surgery? A negative answer. Obes Surg. 2006;16:870–8.CrossRefPubMed
11.
Lin E, Phillips LS, Ziegler TR, et al. Increases in adiponectin predict improved liver, but not peripheral, insulin sensitivity in severely obese women during weight loss. Diabetes. 2007;56:735–42.CrossRefPubMed
12.
Vendrell J, Broch M, Vilarrasa N, et al. Resistin, adiponectin, ghrelin, leptin, and proinflammatory cytokines: relationships in obesity. Obes Res. 2004;12:962–71.CrossRefPubMed
13.
Serra A, Granada ML, Romero R, et al. The effect of bariatric surgery on adipocytokines, renal parameters and other cardiovascular risk factors in severe and very severe obesity: 1-year follow-up. Clin Nutr. 2006;25:400–8.CrossRefPubMed
14.
Coughlin CC, Finck BN, Eagon JC, et al. Effect of marked weight loss on adiponectin gene expression and plasma concentrations. Obesity (Silver Spring). 2007;15:640–5.CrossRef
15.
de Carvalho CP, Marin DM, de Souza AL, et al. GLP-1 and adiponectin: effect of weight loss after dietary restriction and gastric bypass in morbidly obese patients with normal and abnormal glucose metabolism. Obes Surg. 2009;19:313–20.CrossRefPubMed
16.
Vilarrasa N, Vendrell J, Sanchez-Santos R, et al. Effect of weight loss induced by gastric bypass on proinflammatory interleukin-18, soluble tumour necrosis factor-alpha receptors. C-reactive protein and adiponectin in morbidly obese patients. Clin Endocrinol (Oxf). 2007;67:679–86.CrossRef
17.
Faraj M, Havel PJ, Phelis S, et al. Plasma acylation-stimulating protein, adiponectin, leptin, and ghrelin before and after weight loss induced by gastric bypass surgery in morbidly obese subjects. J Clin Endocrinol Metab. 2003;88:1594–602.CrossRefPubMed
18.
Garcia de laTorre N, Rubio MA, Bordiu E, et al. Effects of weight loss after bariatric surgery for morbid obesity on vascular endothelial growth factor-A, adipocytokines, and insulin. J Clin Endocrinol Metab. 2008;93:4276–81.CrossRef
19.
Trakhtenbroit MA, Leichman JG, Algahim MF, et al. Body weight, insulin resistance, and serum adipokine levels 2 years after 2 types of bariatric surgery. Am J Med. 2009;122:435–42.CrossRefPubMed
20.
Swarbrick MM, Austrheim-Smith IT, Stanhope KL, et al. Circulating concentrations of high-molecular-weight adiponectin are increased following Roux-en-Y gastric bypass surgery. Diabetologia. 2006;49:2552–8.CrossRefPubMed
21.
Whitson BA, Leslie DB, Kellogg TA, et al. Adipokine response in diabetics and nondiabetics following the Roux-en-Y gastric bypass: a preliminary study. J Surg Res. 2007;142:295–300.CrossRefPubMed
22.
Whitson BA, Leslie DB, Kellogg TA, et al. Entero-endocrine changes after gastric bypass in diabetic and nondiabetic patients: a preliminary study. J Surg Res. 2007;141:31–9.CrossRefPubMed
23.
Diker D, Vishne T, Maayan R, et al. Impact of gastric banding on plasma adiponectin levels. Obes Surg. 2006;16:1057–61.CrossRefPubMed
24.
Ram E, Vishne T, Maayan R, et al. The relationship between BMI, plasma leptin, insulin and proinsulin before and after laparoscopic adjustable gastric banding. Obes Surg. 2005;15:1456–62.CrossRefPubMed
25.
Haider DG, Schindler K, Schaller G, et al. Increased plasma visfatin concentrations in morbidly obese subjects are reduced after gastric banding. J Clin Endocrinol Metab. 2006;91:1578–81.CrossRefPubMed
26.
Engl J, Bobbert T, Ciardi C, et al. Effects of pronounced weight loss on adiponectin oligomer composition and metabolic parameters. Obesity (Silver Spring). 2007;15:1172–8.CrossRef
27.
Poitou C, Lacorte JM, Coupaye M, et al. Relationship between single nucleotide polymorphisms in leptin, IL6 and adiponectin genes and their circulating product in morbidly obese subjects before and after gastric banding surgery. Obes Surg. 2005;15:11–23.CrossRefPubMed
28.
Kopp HP, Krzyzanowska K, Mohlig M, et al. Effects of marked weight loss on plasma levels of adiponectin, markers of chronic subclinical inflammation and insulin resistance in morbidly obese women. Int J Obes (Lond). 2005;29:766–71.CrossRef
29.
American Dietetic Association. Evidence analysis manual: steps in the ADA evidence analysis process. Chicago: American Dietetic Association; 2008.
30.
Buchwald H. Consensus conference statement bariatric surgery for morbid obesity: health implications for patients, health professionals, and third-party payers. Surg Obes Relat Dis. 2005;1:371–81.CrossRefPubMed
31.
Bloomberg RD, Fleishman A, Nalle JE, et al. Nutritional deficiencies following bariatric surgery: what have we learned? Obes Surg. 2005;15:145–54.CrossRefPubMed
32.
Kotidis EV, Koliakos GG, Baltzopoulos VG, et al. Serum ghrelin, leptin and adiponectin levels before and after weight loss: comparison of three methods of treatment—a prospective study. Obes Surg. 2006;16:1425–32.CrossRefPubMed
33.
Mari A, Manco M, Guidone C, et al. Restoration of normal glucose tolerance in severely obese patients after bilio-pancreatic diversion: role of insulin sensitivity and beta cell function. Diabetologia. 2006;49:2136–43.CrossRefPubMed
34.
Despres JP, Golay A, Sjostrom L. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353:2121–34.CrossRefPubMed
35.
Esposito K, Pontillo A, Di Palo C, et al. Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. JAMA. 2003;289:1799–804.CrossRefPubMed
36.
Antuna-Puente B, Feve B, Fellahi S, et al. Adipokines: the missing link between insulin resistance and obesity. Diabetes Metab. 2008;34:2–11.CrossRefPubMed
37.
Cottam DR, Mattar SG, Barinas-Mitchell E, et al. The chronic inflammatory hypothesis for the morbidity associated with morbid obesity: implications and effects of weight loss. Obes Surg. 2004;14:589–600.CrossRefPubMed
38.
Hotta K, Funahashi T, Arita Y, et al. Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol. 2000;20:1595–9.PubMed
39.
Li S, Shin JJ, Ding EL, et al. Adiponectin levels and risk of type 2 diabetes: a systematic review and meta-analysis. JAMA. 2009;302:179–88.CrossRefPubMed
40.
Abeles D, Shikora SA. Bariatric surgery: current concepts and future directions. Aesthet Surg J. 2008;28:79–84.CrossRefPubMed
41.
Buchwald H, Estok R, Fahrbach K, et al. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. Am J Med. 2009;122:248–56.CrossRefPubMed
42.
Fetner R, McGinty J, Russell C, et al. Incretins, diabetes, and bariatric surgery: a review. Surg Obes Relat Dis. 2005;1:589–97. discussion 97–8.CrossRefPubMed
43.
Cummings DE, Overduin J, Foster-Schubert KE, et al. Role of the bypassed proximal intestine in the anti-diabetic effects of bariatric surgery. Surg Obes Relat Dis. 2007;3:109–15.CrossRefPubMed
44.
Garaulet M, Hernandez-Morante JJ, de Heredia FP, et al. Adiponectin, the controversial hormone. Public Health Nutr. 2007;10:1145–50.CrossRefPubMed
45.
Weyer C, Funahashi T, Tanaka S, et al. Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab. 2001;86:1930–5.CrossRefPubMed
46.
Esposito K, Giugliano G, Scuderi N, et al. Role of adipokines in the obesity-inflammation relationship: the effect of fat removal. Plast Reconstr Surg. 2006;118:1048–57. discussion 58–9.CrossRefPubMed
47.
Tschritter O, Fritsche A, Thamer C, et al. Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism. Diabetes. 2003;52:239–43.CrossRefPubMed
48.
Samuel I, Mason EE, Renquist KE, et al. Bariatric surgery trends: an 18-year report from the international bariatric surgery registry. Am J Surg. 2006;192:657–62.CrossRefPubMed
49.
Pajvani UB, Hawkins M, Combs TP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem. 2004;279:12152–62.CrossRefPubMed
50.
Xu A, Chan KW, Hoo RL, et al. Testosterone selectively reduces the high molecular weight form of adiponectin by inhibiting its secretion from adipocytes. J Biol Chem. 2005;280:18073–80.CrossRefPubMed
51.
Pender C, Goldfine ID, Tanner CJ, et al. Muscle insulin receptor concentrations in obese patients post bariatric surgery: relationship to hyperinsulinemia. Int J Obes Relat Metab Disord. 2004;28:363–9.CrossRefPubMed
52.
Gannage-Yared MH, Yaghi C, Habre B, et al. Osteoprotegerin in relation to body weight, lipid parameters insulin sensitivity, adipocytokines, and C-reactive protein in obese and non-obese young individuals: results from both cross-sectional and interventional study. Eur J Endocrinol. 2008;158:353–9.CrossRefPubMed
53.
Guldstrand M, Ahren B, Adamson U. Improved beta-cell function after standardized weight reduction in severely obese subjects. Am J Physiol Endocrinol Metab. 2003;284:E557–65.PubMed
54.
Engl J, Sturm W, Sandhofer A, et al. Effect of pronounced weight loss on visceral fat, liver steatosis and adiponectin isoforms. Eur J Clin Invest. 2008;38:238–44.CrossRefPubMed
55.
Alverdy JC, Prachand V, Flanagan B, et al. Bariatric surgery: a history of empiricism, a future in science. J Gastrointest Surg. 2009;13:465–77.CrossRefPubMed
56.
Lin E, Gletsu N, Fugate K, et al. The effects of gastric surgery on systemic ghrelin levels in the morbidly obese. Arch Surg. 2004;139:780–4.CrossRefPubMed
57.
Schauer PR, Ikramuddin S, Gourash W, et al. Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Ann Surg. 2000;232:515–29.CrossRefPubMed
58.
Schauer PR, Burguera B, Ikramuddin S, et al. Effect of laparoscopic Roux-en Y gastric bypass on type 2 diabetes mellitus. Ann Surg. 2003;238:467–84. discussion 84–5.PubMed
59.
Capella RF, Capella JF. Reducing early technical complications in gastric bypass surgery. Obes Surg. 1997;7:149–56. discussion 57.CrossRefPubMed
60.
Mason EE, Ito C. Gastric bypass in obesity. Surg Clin North Am. 1967;47:1345–51.PubMed
61.
Williams MD, Champion JK. Linear technique of laparoscopic Roux-en-Y gastric bypass. Surg Technol Int. 2004;13:101–5.PubMed
62.
Fobi MA, Lee H, Igwe Jr D, et al. Revision of failed gastric bypass to distal Roux-en-Y gastric bypass: a review of 65 cases. Obes Surg. 2001;11:190–5.CrossRefPubMed
63.
Fobi MA, Lee H, Holness R, et al. Gastric bypass operation for obesity. World J Surg. 1998;22:925–35.CrossRefPubMed
64.
Salmon PA. Gastroplasty with distal gastric bypass: a new and more successful weight loss operation for the morbidly obese. Can J Surg. 1988;31:111–3.PubMed
65.
MacLean LD, Rhode BM, Nohr CW. Late outcome of isolated gastric bypass. Ann Surg. 2000;231:524–8.CrossRefPubMed
66.
Ren CJ, Fielding GA. Laparoscopic adjustable gastric banding: surgical technique. J Laparoendosc Adv Surg Tech A. 2003;13:257–63.CrossRefPubMed
67.
Mittermair RP, Weiss H, Nehoda H, et al. Laparoscopic Swedish adjustable gastric banding: 6-year follow-up and comparison to other laparoscopic bariatric procedures. Obes Surg. 2003;13:412–7.CrossRefPubMed
68.
Mason EE, Doherty C, Cullen JJ, et al. Vertical gastroplasty: evolution of vertical banded gastroplasty. World J Surg. 1998;22:919–24.CrossRefPubMed
Metadata
Title
A Review of Weight Loss Following Roux-en-Y Gastric Bypass vs Restrictive Bariatric Surgery: Impact on Adiponectin and Insulin
Authors
Katrina L. Butner
Sharon M. Nickols-Richardson
Susan F. Clark
Warren K. Ramp
William G. Herbert
Publication date
01-05-2010
Publisher
Springer-Verlag
Published in
Obesity Surgery / Issue 5/2010
Print ISSN: 0960-8923
Electronic ISSN: 1708-0428
DOI
https://doi.org/10.1007/s11695-010-0089-z

Other articles of this Issue 5/2010

Obesity Surgery 5/2010 Go to the issue

Letter to the Editor

Internal Hernias and Nonclosure of Mesenteric Defects During Laparoscopic Roux-en-Y Gastric Bypass

Other

Can a Short Course of Prophylactic Low-dose Proton Pump Inhibitor Therapy Prevent Stomal Ulceration After Laparoscopic Roux-en-Y Gastric Bypass?

Clinical Research

Sleeve Gastrectomy as Sole and Definitive Bariatric Procedure: 5-Year Results for Weight Loss and Ghrelin

Clinical Report

Comparison of Early and Late Changes in Immunoglobulins and Acute Phase Reactants after Laparoscopic Adjustable Gastric Banding in Patients with Morbid Obesity

Letter to the Editor

Response to the Letter to the Editor “Bariatric Surgery and the Assessment of Copper and Zinc Nutriture” by Leslie M. Klevay

Clinical Research

Hepatic Gene Expression of Caucasian and African-American Patients with Obesity-Related Non-Alcoholic Fatty Liver Disease